Novocure Stock News

Related Stocks: NVCR ,

The stock price of Novocure, a company working on an innovative cancer treatment alternative using electric fields, has seen a fall of 15% in a week, while it is down 22% over the last month, followin

During the last session, NovoCure Limited (NASDAQ:NVCR)s traded shares were 0.76 million, with the beta value of the company hitting 0.93. At the end of the trading day, the stocks price was $99.73, reflecting an intraday gain of 6.85% or $6.39. The 52-week high for the NVCR share is $232.76, that puts it down -133.39 NovoCure Limited (NASDAQ: NVCR)s Stock Is Down -16.48% Since The Beginning Of The Year, Likely To Sustain The Trend In 2021 Read More »

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences. William Doyle, Novocures Executive Chairman, and Ashley Cordova, Novocures Chief Financial Officer, will participate in the 33rd Annual 2021 Piper Sandler Healthcare Conference on November 30, 2021. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 1 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences. William Doyle, Novocure's Executive Chairman, and Ashley Cordova,

Final data from LUNAR trial anticipated year-end 2022 Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the phase 3 pivotal LUNAR trial evaluating the efficacy of

Novocure Ltd (NASDAQ: NVCR ) has released updated data from the Phase 2 pilot 2-THE-TOP of Tumor Treating Fields (TTFields) together with pembrolizumab and temozolomide for newly diagnosed glioblastoma (GBM). Of the 19 patients with follow-up over nine months, the median progression-free survival Full story available on Benzinga.com

Novocure Ltd (NASDAQ: NVCR) has released updated data from the Phase 2 pilot 2-THE-TOP of Tumor Treating Fields (TTFields) together with pembrolizumab and temozolomide for newly diagnosed glioblast

Median progression-free survival was at least 11.2 months in patients with greater than 9 months of follow-up Partial or complete response was detected in 24% of patients Novocure (NASDAQ: NVCR) t

NovoCure Limited (NVCR) CEO Asaf Danziger on Q3 2021 Results - Earnings Call Transcript

Novocure's stock keeps sliding, but the company continues to perform.

Is it time to buy this stock nearly at its 52 week low?

These stocks are down but not out.

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced that it will report financial results for the third quarter 2021 on Thursday, October 28, 2021.

Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating Fields (TTFields) together with Roche's atezoli